Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update for 6/23/2020

6/23/2020

 
​EIDD-2801
 
Ridgeback Biotherapeutics is developing EIDD-2801, an oral nucleoside analog that inhibits the replication of RNA viruses such as influenza and coronaviruses. In May, Ridgeback licensed manufacturing and development to Merck. Pending approval of the licensing deal with Merck, Ridgeback is moving forward with development.
  • EIDD-2801 is dosed twice a day for 5 days.
  • Ridgeback announced that in a 15-day, 122 patient, Phase I trial (NCT04392219), administration of EIDD-2801 produced no safety issues at serum levels estimated to reduce pulmonary virus levels.
  • Ridgeback is evaluating the effect of EIDD-2801 on clearing the COVID-19 virus in a 28-day, 60 patient Phase II trial (NCT04405739) of newly diagnosed, hospitalized patients with COVID-19 pneumonia.
  • Ridgeback is also evaluating the effect of EIDD-2801 on clearing the COVID-19 virus in a 28-day, 44 patient, Phase II trial (NCT04405570) of newly diagnosed, non-hospitalized patients with COVID-19 pneumonia.
 
Remdesivir
 
Gilead is evaluating remdesivir administered as an inhalation in a Phase I study in healthy volunteers and hopes to initiate a COVID-19 patient trial in August 2020, with this formulation.
 
Hydroxychloroquine
 
NIH discontinued the ORCHID study in June 2020. The Orchid trial was evaluating hydroxychloroquine as a treatment for hospitalized patients with COVID-19. The discontinuation was recommended by the data and safety monitoring board after an interim analysis of data from 470 patients indicated that while hydroxychloroquine was safe, it was unlikely to demonstrate a beneficial effect.
 
Dexamethasone
 
You can get an early look at the dexamethasone data from the RECOVERY trial in a draft of the paper that is available on an editorial server.

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.